Marvelon (Desogestrel, Ethinylestradiol)

Desogestrel is a synthetic progestogen that suppresses the mid‑cycle luteinising hormone surge, thereby inhibiting ovulation. Ethinylestradiol is a synthetic estrogen that provides negative feedback on the hypothalamic‑pituitary axis, stabilises the endometrium and thickens cervical mucus, making sperm penetration difficult. Together they create a hormonal environment that prevents fertilisation and implantation.

The prescribed regimen of Marvelon is determined by the treating healthcare professional. Typically the product is supplied as a 21‑day active tablet series followed by a 7‑day placebo or hormone‑free interval, but the exact dosing schedule, including any missed‑pill instructions, must be individualized by the prescriber based on clinical guidelines and patient factors.

Marvelon is contraindicated during pregnancy because its purpose is to prevent conception; if pregnancy occurs, the product should be discontinued and medical advice sought. Limited data are available for use while breastfeeding, and most guidelines advise against continued use during lactation unless the benefits outweigh potential risks, so a healthcare provider should evaluate each case.

To place an order, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature‑controlled requirements), and assistance with import documentation.

Marvelon contains a third‑generation progestogen (desogestrel) and a low‑dose estrogen (ethinylestradiol 30 µg), which may offer a more favorable bleeding profile and lower androgenic side effects compared with older formulations that use higher estrogen doses or first‑generation progestins. However, individual response varies, and clinicians consider efficacy, safety, tolerability, and patient preference when selecting a specific pill.

Marvelon tablets should be stored at ambient temperature, preferably below 25 °C, in their original blister pack to protect from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured. No refrigeration is required.

Marvelon is taken orally, once daily, at the same time each day, for 21 consecutive days followed by a 7‑day interval without active tablets (or with placebo tablets, depending on the pack). Swallow each tablet whole with water; do not split, crush, or chew. If a dose is missed, follow the specific missed‑pill instructions provided by the prescriber.

The most serious adverse events linked to combined oral contraceptives include venous thromboembolism, arterial thrombosis (such as stroke or myocardial infarction), and severe hypertension. These risks are higher in women who smoke, are over 35 years old, have a personal or family history of clotting disorders, or have certain cardiovascular conditions. Prompt medical attention is required if symptoms of clotting or severe headache occur.

Marvelon is contraindicated in women with a history of thromboembolic disorders, known or suspected estrogen‑dependent tumors (e.g., breast cancer), uncontrolled hypertension, severe liver disease, or those who are pregnant or breastfeeding without medical approval. It should also be avoided in smokers over 35 years of age and in individuals taking medications that markedly reduce contraceptive efficacy, unless alternative protection is used.